Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Impact · against what's priced in

Vaxcyte is hitting key clinical and operational milestones, most notably the transition of VAX-31 into a pivotal adult study in December 2025. The combination of positive Phase 2 data for infants and a massive $2.7 billion cash pile significantly derisks the path to commercialization.

PCVX+0.70

No priced-in read yet